

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Rivaroxaban for the prevention of venous thromboembolism after major orthopaedic surgery of the lower limbs

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> ▪ Bayer healthcare (rivaroxiban) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> ▪ Action Heart ▪ Afiya Trust ▪ Age Concern England ▪ Anticoagulation Europe ▪ Black Health Agency ▪ Blood Pressure Association ▪ Brain and Spine Foundation ▪ British Cardiac Patients Association ▪ British Ethnic Health Awareness Foundation (BEHAF) ▪ British Hip Society ▪ British Lung Foundation ▪ British Vascular Foundation ▪ Cardiomyopathy Association ▪ Chinese National Healthy Living Centre ▪ Confederation of Indian Organisations ▪ Counsel and Care ▪ Diabetes UK ▪ Different Strokes ▪ Equalities National Council ▪ Heart Care Partnership UK ▪ HEART UK ▪ Help the Aged ▪ Lifeblood: The Thrombosis Charity ▪ Muslim Council of Great Britain ▪ Muslim Health Network ▪ Neurological Alliance ▪ Pulmonary Hypertension Association ▪ SADS UK 	<p><u>General</u></p> <ul style="list-style-type: none"> ▪ Age Concern Cymru ▪ Board of Community Health Councils in Wales ▪ British National Formulary ▪ Department of Health, Social Services and Public Safety for Northern Ireland ▪ Medicines and Healthcare products Regulatory Agency (MHRA) ▪ National Public Health Service for Wales ▪ NHS Alliance ▪ NHS Confederation ▪ NHS Purchasing and Supply Agency ▪ NHS Quality Improvement Scotland ▪ Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> ▪ Amdipharm plc (bemiparin sodium) ▪ GlaxoSmithKline (fondaparinux sodium) ▪ Leo Laboratories (tinzaparin sodium) ▪ Pfizer Ltd (dalteparin sodium) ▪ Sanofi-Aventis Ltd (enoxaparin sodium) ▪ Valeant Pharmaceuticals Ltd (reviparin sodium) ▪ Boehringer Ingelheim Ltd debigatran <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> ▪ Antithrombotic Trialists' (ATT) Collaboration ▪ British Society for Cardiovascular Research ▪ British Stroke Research Group ▪ Cochrane Heart Group

Deleted: Schering Pharma

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> ▪ South Asian Health Foundation ▪ Specialised Healthcare Alliance ▪ Stroke Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> ▪ Anticoagulation Specialist Association ▪ Association of British Neurologists ▪ Association of Surgeons of Great Britain and Ireland ▪ British Association for Nursing in Cardiac Care ▪ British Association for Service to the Elderly ▪ British Association for Surgery of the Knee ▪ British Association of Stroke Physicians ▪ British Cardiac Society ▪ British Cardiovascular Intervention Society ▪ British Geriatrics Society ▪ British Heart Foundation ▪ British Hypertension Society ▪ British Lung Foundation ▪ British Orthopaedic Association ▪ British Society for Haematology ▪ British Society for Haemostasis and Thrombosis ▪ British Thoracic Society ▪ British Vein Institute ▪ Clinical Leaders of Thrombosis (CLOT) ▪ College of Emergency Medicine ▪ Coronary Prevention Group ▪ National Association of Primary Care ▪ National Heart Forum (UK) ▪ Primary Care Cardiovascular Society ▪ Primary Care Neurology Society ▪ Royal College of Anaesthetists ▪ Royal College of General Practitioners ▪ Royal College of Nursing ▪ Royal College of Pathologists ▪ Royal College of Physicians (Cardiology Committee & Intercollegiate Stroke Working Party) ▪ Royal College of Surgeons 	<ul style="list-style-type: none"> ▪ Cochrane Peripheral Vascular Disease Group ▪ Cochrane Stroke Group ▪ Heart Research UK ▪ National Heart Research Fund ▪ Oxford Stroke Prevention Research Unit ▪ Policy Research Institute on Ageing and Ethnicity ▪ Research Institute for the Care of the Elderly ▪ Thrombosis Research Institute ▪ UK Safe Implementation for Thrombolysis Study (SITS) ▪ UK Stroke Research Network ▪ Wellcome Trust Cardiovascular Research Initiative <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> ▪ Evidence Review Group tbc ▪ National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> ▪ National Collaborating Centre for Acute Care <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> ▪ (None)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> ▪ Royal Pharmaceutical Society ▪ Royal Society of Medicine - Forum on Intellectual Disabilities ▪ Royal Society of Medicine's Cardiothoracic Section ▪ Society for Cardiological Science and Technology ▪ Society for Vascular Technology ▪ Society for Vascular Ultrasound ▪ Society of British Neurological Surgeons ▪ Society of Cardiothoracic Surgeons of Great Britain and Ireland ▪ Society of Vascular Nurses ▪ United Kingdom Clinical Pharmacy Association ▪ Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> ▪ Department of Health ▪ Coventry Teaching PCT ▪ Hammersmith and Fulham PCT ▪ Welsh Assembly Government 	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.